Literature DB >> 14503918

Validation of real-time RT-PCR for analysis of human breast cancer cell lines resistant or sensitive to treatment with antiestrogens.

P de Cremoux1, C Tran-Perennou, B L Brockdorff, E Boudou, N Brünner, H Magdelénat, A E Lykkesfeldt.   

Abstract

Using a quantitative real-time RT-PCR technique we have compared the expression of a number of genes in two different human breast cancer model systems for development of acquired resistance to antiestrogens. The model system developed at the Danish Cancer Society comprises the cell lines MCF-7, MCF-7/TAMR-1, MCF-7/182R-6 and MCF-7/182R-7, and the model system developed at the Lombardi Cancer Research Center consists of the cell lines MCF-7/LCC1, MCF-7/LCC2 and MCF-7/LCC9. The findings on the well-known parameters estrogen receptor (ER)alpha, progesterone receptor (PR) and epidermal growth factor receptor (EGFR) are in good agreement with previous reports, thus documenting the usefulness of the real-time RT-PCR technique for multiparametric RNA analysis. The gene expression levels in the two model systems were found to be quite similar in relation to ERalpha, AIB1 (amplified in breast cancer-1), breast cancer antiestrogen resistance gene 1 (BCAR1) and ErbB-2 mRNA expression, whereas significant differences were observed on the expression of ERbeta, multidrug resistance gene 1 (MDR1), PR and EGFR. Furthermore, the presented data suggest that ERbeta, AIB1, BCAR1, CYP19 and MDR1 are unlikely to be causally involved in development of antiestrogen resistance in these breast cancer cell lines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14503918     DOI: 10.1677/erc.0.0100409

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  13 in total

1.  RCL2, a new fixative, preserves morphology and nucleic acid integrity in paraffin-embedded breast carcinoma and microdissected breast tumor cells.

Authors:  Christophe Delfour; Pascal Roger; Caroline Bret; Marie-Laurence Berthe; Philippe Rochaix; Nicolas Kalfa; Pierre Raynaud; Frédéric Bibeau; Thierry Maudelonde; Nathalie Boulle
Journal:  J Mol Diagn       Date:  2006-05       Impact factor: 5.568

2.  Evaluation of BrightGen HR RT-qDx assay to detect nuclear receptors mRNA overexpression in FFPE breast cancer tissue samples for selection of tamoxifen therapy.

Authors:  Hye-Young Wang; Sangjung Park; Sunghyun Kim; Sungwoo Ahn; Dongsup Lee; Seungil Kim; Dongju Jung; Kwang Hwa Park; Hyeyoung Lee
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

Review 3.  Consensus reference gene(s) for gene expression studies in human cancers: end of the tunnel visible?

Authors:  R N Sharan; S Thangminlal Vaiphei; Saibadaiahun Nongrum; Joshua Keppen; Mandahakani Ksoo
Journal:  Cell Oncol (Dordr)       Date:  2015-09-18       Impact factor: 6.730

Review 4.  CAS proteins in normal and pathological cell growth control.

Authors:  Nadezhda Tikhmyanova; Joy L Little; Erica A Golemis
Journal:  Cell Mol Life Sci       Date:  2009-11-25       Impact factor: 9.261

5.  Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.

Authors:  Thomas Frogne; Rikke V Benjaminsen; Katrine Sonne-Hansen; Boe S Sorensen; Ebba Nexo; Anne-Vibeke Laenkholm; Louise M Rasmussen; David J Riese; Patricia de Cremoux; Jan Stenvang; Anne E Lykkesfeldt
Journal:  Breast Cancer Res Treat       Date:  2008-04-14       Impact factor: 4.872

6.  Heregulin negatively regulates transcription of ErbB2/3 receptors via an AKT-mediated pathway.

Authors:  Smita Awasthi; Anne W Hamburger
Journal:  J Cell Physiol       Date:  2014-11       Impact factor: 6.384

7.  Detection of tumor cell-specific mRNA in the peripheral blood of patients with breast cancer—evaluation of several markers with real-time reverse transcription-PCR.

Authors:  Ulrich Andergassen; Simone Hofmann; Alexandra C Kölbl; Christian Schindlbeck; Julia Neugebauer; Stefan Hutter; Verena Engelstädter; Matthias Ilmer; Klaus Friese; Udo Jeschke
Journal:  Int J Mol Sci       Date:  2013-01-08       Impact factor: 5.923

8.  Dietary phenethyl isothiocyanate alters gene expression in human breast cancer cells.

Authors:  Young Jin Moon; Daniel A Brazeau; Marilyn E Morris
Journal:  Evid Based Complement Alternat Med       Date:  2010-09-28       Impact factor: 2.629

9.  TFRC and ACTB as the best reference genes to quantify Urokinase Plasminogen Activator in breast cancer.

Authors:  Keivan Majidzadeh-A; Rezvan Esmaeili; Nasrin Abdoli
Journal:  BMC Res Notes       Date:  2011-06-25

10.  Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide.

Authors:  Keyvan Rezaï; François Lokiec; Isabelle Grandjean; Sophie Weill; Patricia de Cremoux; Vincent Bordier; Richard Ekue; Mickael Garcia; Marie-France Poupon; Didier Decaudin
Journal:  BMC Pharmacol       Date:  2007-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.